Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) ("Valneva” or the "Company”), a specialty vaccine company, today announces that it has filed a prospectus supplement as part of the renewal of its ...
January 2025 - Cingulate completed its final FDA-required study, a food effect study utilizing a single 50-mg dose of ...
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for tolebrutinib for the treatment of non-relapsing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback